PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells
This study further supports the available knowledge about the anti-inflammatory/antifibrotic mechanisms of nerandomilast and provides novel insights into the mode of action and signalling pathways influenced by nerandomilast treatment of lung fibrosis.
Authors
- Dennis Reininger
- Peter Nickolaus (ORCID: https://orcid.org/0000-0001-7811-3994)
- Baerbel Laemmle
- Katrin Fundel‐Clemens (ORCID: https://orcid.org/0000-0002-7250-9397)
- Karsten Quast (ORCID: https://orcid.org/0000-0003-3922-5701)
- Lutz Wollin (ORCID: https://orcid.org/0000-0002-3617-5772)
- Christoph H. Mayr (ORCID: https://orcid.org/0000-0001-5353-4768)
- Franziska Herrmann (ORCID: https://orcid.org/0009-0004-1234-0931)
Institutions
- Boehringer Ingelheim (Germany) (DE)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-08-25
- DOI
- https://doi.org/10.1111/bph.17303
- Citations
- 30
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 12.57
Funders
- Boehringer Ingelheim